Update of PDE5 inhibitors as treatment of ED / 中华男科学杂志
National Journal of Andrology
;
(12): 552-555, 2005.
Article
in Chinese
| WPRIM
| ID: wpr-339483
ABSTRACT
Erectile dysfunction is a common ailment in middle-aged and old men. The management of ED has entered a new stage since sildenafil was used to treat ED in 1998. Sildenafil became the first-line treatment for its efficacy and safety. In recent years, new PDE5 inhibitors--vardenafil and tadalafil came into market in succession, providing more options available for oral therapy. This review is about the development of preclinical and clinical medicine research on the three PDE5 inhibitors, and provide information for clinical choices.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Phosphodiesterase Inhibitors
/
Piperazines
/
Purines
/
Sulfones
/
Therapeutic Uses
/
Drug Therapy
/
Sildenafil Citrate
/
Erectile Dysfunction
Limits:
Humans
/
Male
Language:
Chinese
Journal:
National Journal of Andrology
Year:
2005
Type:
Article
Similar
MEDLINE
...
LILACS
LIS